Analysis of Clinical Outcomes and Cost Effectiveness of Neuromuscular Blocking Drug Reversal in Patients Classified as Obese

Obesity predisposes patients to heightened risks of adverse outcomes following surgery, including residual neuromuscular blockade and postoperative complications. The administration of non-depolarizing neuromuscular agents (NMBAs) is fundamental for muscle relaxation and optimal surgical conditions. However, the subsequent reversal of these blockers with agents like sugammadex or neostigmine is crucial to mitigate these risks. While sugammadex is recognized as a clinically superior choice due to its rapid and more complete reversal, its extensive use is often limited by cost, presenting challenges in obese patients who already face increased susceptibility to complications. This project evaluates the cost-effectiveness of sugammadex versus neostigmine in obese patients undergoing general anesthesia. Employing the PET process of the Johns Hopkins Nursing Evidence-Based Practice (EBP) Model, the project develops evidence-based recommendations. By conducting evidence review and analyzing literature on clinical and economic outcomes, including postoperative complications and costs, anesthesia providers will receive guidance in optimizing patient care and resource utilization.